51,445 Shares in Inhibrx, Inc. (NASDAQ:INBX) Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 51,445 shares of the company’s stock, valued at approximately $792,000. Bank of New York Mellon Corp owned 0.36% of Inhibrx as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. New York State Common Retirement Fund bought a new stake in Inhibrx in the 4th quarter valued at $53,000. Rhumbline Advisers bought a new position in shares of Inhibrx in the fourth quarter valued at about $228,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Inhibrx in the fourth quarter valued at about $47,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Inhibrx during the 4th quarter worth about $348,000. Finally, Exchange Traded Concepts LLC acquired a new position in Inhibrx in the 4th quarter valued at about $148,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Price Performance

NASDAQ:INBX opened at $14.22 on Wednesday. The stock has a 50 day simple moving average of $13.32 and a 200 day simple moving average of $14.62. Inhibrx, Inc. has a 1-year low of $10.80 and a 1-year high of $35.42.

Inhibrx (NASDAQ:INBX) last posted its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The firm had revenue of $0.10 million during the quarter. On average, research analysts forecast that Inhibrx, Inc. will post 104.88 earnings per share for the current year.

Analyst Ratings Changes

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.